Neuland Laboratories Limited (NEULANDLAB.BO)
- Previous Close
12,434.70 - Open
12,699.95 - Bid 12,528.95 x --
- Ask 12,637.00 x --
- Day's Range
12,498.00 - 12,765.30 - 52 Week Range
5,557.00 - 18,089.55 - Volume
1,779 - Avg. Volume
2,400 - Market Cap (intraday)
161.025B - Beta (5Y Monthly) 0.45
- PE Ratio (TTM)
53.69 - EPS (TTM)
233.77 - Earnings Date May 15, 2025
- Forward Dividend & Yield 14.00 (0.11%)
- Ex-Dividend Date Jul 12, 2024
- 1y Target Est
17,600.00
Neuland Laboratories Limited manufactures and sells active pharmaceutical ingredients (APIs) in India, Europe, the United States, and internationally. It also provides custom manufacturing solutions, as well as peptide synthesis services. Neuland Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.
www.neulandlabs.com1,643
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: NEULANDLAB.BO
View MorePerformance Overview: NEULANDLAB.BO
Trailing total returns as of 5/12/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NEULANDLAB.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NEULANDLAB.BO
View MoreValuation Measures
Market Cap
159.54B
Enterprise Value
158.66B
Trailing P/E
53.20
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.70
Price/Book (mrq)
11.43
Enterprise Value/Revenue
10.64
Enterprise Value/EBITDA
33.69
Financial Highlights
Profitability and Income Statement
Profit Margin
19.55%
Return on Assets (ttm)
--
Return on Equity (ttm)
--
Revenue (ttm)
15.33B
Net Income Avi to Common (ttm)
3B
Diluted EPS (ttm)
233.77
Balance Sheet and Cash Flow
Total Cash (mrq)
1.9B
Total Debt/Equity (mrq)
7.85%
Levered Free Cash Flow (ttm)
--